677 related articles for article (PubMed ID: 23974116)
21. Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.
Tomassi S; Romanelli A; Zwergel C; Valente S; Mai A
J Med Chem; 2021 Aug; 64(16):11774-11797. PubMed ID: 34351144
[TBL] [Abstract][Full Text] [Related]
22. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
Zhu K; Du D; Yang R; Tao H; Zhang H
Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
[TBL] [Abstract][Full Text] [Related]
23. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
He Y; Selvaraju S; Curtin ML; Jakob CG; Zhu H; Comess KM; Shaw B; The J; Lima-Fernandes E; Szewczyk MM; Cheng D; Klinge KL; Li HQ; Pliushchev M; Algire MA; Maag D; Guo J; Dietrich J; Panchal SC; Petros AM; Sweis RF; Torrent M; Bigelow LJ; Senisterra G; Li F; Kennedy S; Wu Q; Osterling DJ; Lindley DJ; Gao W; Galasinski S; Barsyte-Lovejoy D; Vedadi M; Buchanan FG; Arrowsmith CH; Chiang GG; Sun C; Pappano WN
Nat Chem Biol; 2017 Apr; 13(4):389-395. PubMed ID: 28135237
[TBL] [Abstract][Full Text] [Related]
24. Deletion of Polycomb Repressive Complex 2 From Mouse Intestine Causes Loss of Stem Cells.
Koppens MA; Bounova G; Gargiulo G; Tanger E; Janssen H; Cornelissen-Steijger P; Blom M; Song JY; Wessels LF; van Lohuizen M
Gastroenterology; 2016 Oct; 151(4):684-697.e12. PubMed ID: 27342214
[TBL] [Abstract][Full Text] [Related]
25. AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
Zhang KL; Shen QQ; Fang YF; Sun YM; Ding J; Chen Y
Acta Pharmacol Sin; 2019 Dec; 40(12):1587-1595. PubMed ID: 31171828
[TBL] [Abstract][Full Text] [Related]
26. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
Yang CY; Wang S
J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
[TBL] [Abstract][Full Text] [Related]
27. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
28. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
30. Targeting EZH2 as cancer therapy.
Hanaki S; Shimada M
J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.
Wu Y; Hu J; Ding H; Chen L; Zhang Y; Liu R; Xu P; Du D; Lu W; Liu J; Liu Y; Liu YC; Lu J; Zhang J; Yao Z; Luo C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3813-7. PubMed ID: 27289323
[TBL] [Abstract][Full Text] [Related]
32. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
33. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.
Ueda K; Yoshimi A; Kagoya Y; Nishikawa S; Marquez VE; Nakagawa M; Kurokawa M
Cancer Sci; 2014 May; 105(5):512-9. PubMed ID: 24612037
[TBL] [Abstract][Full Text] [Related]
35. Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation.
Bamidele AO; Svingen PA; Sagstetter MR; Sarmento OF; Gonzalez M; Braga Neto MB; Kugathasan S; Lomberk G; Urrutia RA; Faubion WA
Cell Mol Gastroenterol Hepatol; 2019; 7(1):55-71. PubMed ID: 30510991
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
[TBL] [Abstract][Full Text] [Related]
37. SAH derived potent and selective EZH2 inhibitors.
Kung PP; Huang B; Zehnder L; Tatlock J; Bingham P; Krivacic C; Gajiwala K; Diehl W; Yu X; Maegley KA
Bioorg Med Chem Lett; 2015 Apr; 25(7):1532-7. PubMed ID: 25746813
[TBL] [Abstract][Full Text] [Related]
38. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
[TBL] [Abstract][Full Text] [Related]
39. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
40. Discovery, design, and synthesis of indole-based EZH2 inhibitors.
Gehling VS; Vaswani RG; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Dakin LA; Cook AS; Gagnon A; Harmange JC; Audia JE; Cummings RT; Normant E; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2015 Sep; 25(17):3644-9. PubMed ID: 26189078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
